Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Aggressive Prostate Cancer Type Is ‘Fairly Prevalent’

Many clinicians who treat men with prostate cancer may be unfamiliar with the term “treatment-emergent small-cell neuroendocrine prostate cancer” (t-SCNC). That’s because it has been considered a rare phenomenon, previously estimated to occur in about 1% of men with metastatic castrate-resistant prostate cancer (mCRPC). However, a new study has found that it is present in nearly one fifth of men with mCRPC.

Read more.

source: Nick Mulcahy - Medscape